Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
